Peritoneal Dialysis Update — Oct 2, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to your bi-weekly update in Peritoneal Dialysis. Peritonitis dominates this period. There is a bedside method that may let a unit count effluent white cells without waiting for the lab, and three papers on which patients do worst once infection takes hold. Low albumin keeps appearing in those papers, and it ties neatly to the first joint international recommendation on nutrition in peritoneal dialysis. Beyond infection, a small study revives the argument over whether automated cycling erodes residual kidney function faster. A mechanistic review reframes membrane failure as an immune problem. And three studies look at choosing peritoneal dialysis and living with it, in children, in restless sleepers, and in patients still deciding.

Peritonitis remains the complication that ends most peritoneal dialysis careers, so faster diagnosis and sharper prognosis matter. This period offers both.

Diagnosis comes first. Nardelli and colleagues, writing in International Urology and Nephrology, asked whether a nurse or physician with a microscope can replace automated flow cytometry for counting white cells in effluent. In a single Italian centre, forty patients contributed 250 paired samples at peritonitis onset, during follow-up, and as asymptomatic controls. Direct manual counting tracked the automated reference closely. At the point of suspected peritonitis it missed almost no cases and produced no false alarms, with sensitivity around 97 percent. During follow-up, specificity slipped to the low eighties, so the manual count is less clean at telling a resolving episode from a persisting one. The study is small and single-centre, and the onset analysis rests on only thirty-six suspected episodes. The method also depends on the skill of whoever looks down the microscope, and the paper doesn't address that across operators. Still, the evidence supports manual microscopy as a credible stopgap where the lab is far away or closed overnight. The authors see it pairing naturally with home turbidity monitoring.

Once peritonitis is confirmed, the question becomes who does badly. Liu and colleagues, in BMC Nephrology, reviewed 156 hospitalised episodes across three Chinese centres and compared gram-negative, gram-positive and culture-negative infections. Gram-negative peritonitis looked worse on every early measure. Effluent counts were higher, procalcitonin was several-fold higher, and pain scores stayed elevated for well over a week. Gram-negative cases also failed treatment more often, meaning catheter removal or death, in roughly one in five of those patients, against none in the culture-negative group. Mortality, though, did not differ by organism. The only factor tied to death was low serum albumin. The design is retrospective with modest numbers, and the authors themselves call for prospective confirmation.

Tanburoğlu and colleagues, in Medicina, looked at timing rather than organism. They studied 227 patients aged sixty-five and over across nine Turkish centres. Nearly a third of these older patients had peritonitis within six months of starting, and about one in six patients died within a year. In the adjusted model, early peritonitis carried a markedly higher risk of death, roughly elevenfold on the point estimate. That figure deserves heavy discounting. The authors acknowledge only seventeen events against four predictors, and the uncertainty around the estimate is enormous. There is also an internal tension. The number of early episodes was not associated with death, yet having any early episode was. And cardiac disease, strongly linked to death in the unadjusted data, dropped out of the adjusted model. That pattern can mean early peritonitis is a marker of the frailest patients rather than a cause of death in its own right.

So these two papers pull in slightly different directions. Liu finds that the infection itself does not drive mortality and that nutrition does. Tanburoğlu finds early infection is the standout predictor, but with too few deaths to rule out confounding by cardiac burden and frailty. Neither study measured both albumin and peritonitis timing in a model powered for death. A larger cohort that does would settle whether early peritonitis kills older patients or simply flags those already at risk.

Tian and colleagues, in Renal Failure, tried to predict who gets peritonitis at all. They built a nomogram from 372 incident patients at a single Chinese centre. Nine routine variables went in. Lower education, lower haemoglobin, lower albumin and, unexpectedly, lower phosphorus each signalled higher risk. That phosphorus finding most plausibly reflects poor intake rather than anything protective about phosphate. Discrimination was moderate at best, and it faded in the internal validation set beyond six months. The authors are explicit that the tool needs external validation before clinical use. For now it is a hypothesis about risk rather than a ready instrument.

That nutritional signal across all three peritonitis papers leads directly into the period's most substantial document. The International Society of Renal Nutrition and Metabolism and the International Society for Peritoneal Dialysis have issued their first joint practice recommendation on nutrition, published in the Journal of Renal Nutrition. A globally drawn panel of nephrologists, dietitians and dialysis nurses wrote it. It covers five areas: screening and monitoring of nutrition status, dietary recommendations, nutrition for patients who develop complications, supplementation, and education aimed at food literacy and dietary self-management. Formal recommendations were graded using the GRADE framework, while practice points rest on expert consensus. That distinction matters. Much of what will be applied day to day sits on the consensus side, because the underlying trial evidence in peritoneal dialysis nutrition is thin. Even so, this fills a genuine gap where no unified international guidance existed. It also gives some structure to the protein-energy wasting that the peritonitis cohorts keep pointing at.

Moving from infection to the organs being protected, two papers concern what peritoneal dialysis does to residual kidney function and to the membrane itself.

Sun and colleagues, also in Renal Failure, reopen an old argument: does automated peritoneal dialysis erode residual kidney function faster than continuous ambulatory dialysis? In fifty-three newly starting Chinese patients at one centre, the automated group lost residual function faster over the first six months. That held after adjustment, and higher baseline function also predicted faster decline. Prior literature on this question has conflicted, and this study is too small to resolve it. With only nineteen patients on the automated arm and modality chosen rather than randomised, selection is a real concern. The finding adds weight to one side of a live debate. Only a randomised or large, carefully matched comparison would settle it.

Lu and colleagues, in Frontiers in Immunology, offer a perspective on why membranes fail at all. They sort the evidence into three tiers: data from peritoneal dialysis itself, data from other peritoneal injury, and analogies from other organs. In their account, macrophages are the best-established organisers of fibrosis and transport deterioration. Neutrophil extracellular traps carry the strongest dialysis-specific signal, with effluent markers already linked to transport phenotype and technique failure. Macrophage traps rest on very thin evidence. The authors propose that chronic dialysate exposure primes the peritoneum and that peritonitis acts as a second hit. Persisting extracellular DNA might then amplify injury through the cGAS-STING pathway. This is hypothesis rather than clinical evidence. Its value is honesty about how much of the immune story is actually shown in dialysis patients, and it gives a mechanistic reason why each peritonitis episode may cost the membrane something lasting.

The last group of papers turns to the patient's side: choosing peritoneal dialysis and how life on it compares.

In Pediatric Nephrology, Aksoy and colleagues used Turkish national registry data on just over a thousand children. After adjustment for age, era and primary diagnosis, children on peritoneal dialysis survived better than those on haemodialysis. The advantage was clearest in children without congenital urinary tract anomalies aged six and over. The registry is large, but the design cannot escape the fact that sicker children may be steered to haemodialysis. Two inconsistencies stand out. The study is framed as a three-year follow-up yet reports a five-year survival advantage. And the conclusion emphasises benefit in younger patients, while the subgroup data point to children over six. The association is plausible and nationally representative, but residual confounding by indication remains unresolved.

Hu and colleagues, in Frontiers in Neurology, compared restless legs syndrome across modalities in a propensity-matched sample of 280 Chinese patients. Restless legs affected about four in ten patients in both groups. Among those affected, though, clinically significant sleep disturbance was more common on peritoneal dialysis, at nearly three quarters of patients against about half on haemodialysis. Raised beta-2 microglobulin was a shared risk factor across both modalities. The design is cross-sectional, so causality is out of reach. The sleep finding suggests the overnight cycler, or something else about peritoneal dialysis, may compound the burden of restless legs.

Finally, Köksal Cevher and colleagues, in Therapeutic Apheresis and Dialysis, followed 238 Turkish patients facing a kidney replacement decision. Nurse-led education combined with peer support explained far more of the variation in choosing peritoneal dialysis than nurse education alone. The design was not randomised, participation was voluntary, and the reporting rests on model-fit statistics rather than clear rates of uptake. So it supports the idea that peer contact shapes modality choice, without showing by how much.

If you read only one paper from this period, make it the joint international nutrition recommendation in the Journal of Renal Nutrition. It is the first time the nutrition and peritoneal dialysis societies have spoken with one voice. And the peritonitis cohorts this period keep implicating poor nutritional status in who fails and who dies.

Here is what this period adds up to. First, bedside microscopy now has early, single-centre evidence as a near-equivalent to automated counting at peritonitis onset, though it performs less cleanly during follow-up. Second, low albumin is the most consistent prognostic thread across the peritonitis studies, more consistent than organism or timing, and the new nutrition recommendation gives that signal a framework, albeit one built largely on consensus. Third, whether early peritonitis itself drives death in older patients remains unsettled; the striking estimate rests on too few events to separate infection from frailty. Fourth, the question of automated cycling and residual function is reopened, not answered. And watch for prospective work on extracellular traps in effluent, which could turn membrane biology into a measurable risk marker.

That's your Peritoneal Dialysis update for this period. Until next time.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.